For example, the lung adenocarcinoma cell line NCI-H1975 harbours both the primary activating L858R mutation that increases the affinity for the EGFR inhibitor gefitinib and the secondary T790M mutation that imparts resistance to gefitinib [50]. Here, EGFR is linked to lung adenocarcinoma.